Literature DB >> 19372139

The miR-18a* microRNA functions as a potential tumor suppressor by targeting on K-Ras.

Wing Pui Tsang1, Tim Tak Kwok.   

Abstract

The Ras proto-oncogene mediates a wide variety of cellular events and is frequently mutated in cancer. MicroRNAs (miRNAs) may regulate the development of cancer through their effect on the target genes. In the search of miRNAs that target on Ras, miR-18a* is the first time confirmed to target on K-Ras and furthermore not on N- and H-Ras. miR-18a* repression by transfection with anti-miR-18a* inhibitor increased the K-Ras expression as well as the luciferase activity of a reporter construct containing the 3'-untranslated region of K-Ras messenger RNA. Furthermore, the miR-18a* repression also increased the cell proliferation and promoted the anchorage-independent growth in soft agar of human squamous carcinoma A431 cells, colon adenocarcinoma HT-29 cells and fetal hepatic WRL-68 cells. On the other hand, ectopic expression of miR-18a* by transfection with miR-18a* precursor suppressed K-Ras expression, cell proliferation and anchorage-independent growth of A431 cells. The increase in cell proliferation and anchorage-independent growth upon miR-18a* repression was, however, rendered by the Ras inhibitor farnesylthiosalicylic acid. In conclusion, miR-18a* may function as a tumor suppressor by targeting on K-Ras. Therefore, the miRNA may also be a potential therapeutic agent or target for cancer therapy.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19372139     DOI: 10.1093/carcin/bgp094

Source DB:  PubMed          Journal:  Carcinogenesis        ISSN: 0143-3334            Impact factor:   4.944


  85 in total

Review 1.  MicroRNAs: novel biomarkers for gastrointestinal carcinomas.

Authors:  Li Xie; Xiaoping Qian; Baorui Liu
Journal:  Mol Cell Biochem       Date:  2010-04-27       Impact factor: 3.396

2.  Widespread regulatory activity of vertebrate microRNA* species.

Authors:  Jr-Shiuan Yang; Michael D Phillips; Doron Betel; Ping Mu; Andrea Ventura; Adam C Siepel; Kevin C Chen; Eric C Lai
Journal:  RNA       Date:  2010-12-22       Impact factor: 4.942

3.  Species-specific function of microRNA-7702 in human colorectal cancer cells via targeting TADA1.

Authors:  Han Liu; Dongdong Li; Hua Fang; Junnan Ning
Journal:  Am J Transl Res       Date:  2018-08-15       Impact factor: 4.060

4.  Specific and Efficient Regression of Cancers Harboring KRAS Mutation by Targeted RNA Replacement.

Authors:  Sung Jin Kim; Ju Hyun Kim; Bitna Yang; Jin-Sook Jeong; Seong-Wook Lee
Journal:  Mol Ther       Date:  2017-02-01       Impact factor: 11.454

5.  miR-18a downregulates DICER1 and promotes proliferation and metastasis of nasopharyngeal carcinoma.

Authors:  Xi Chen; Juan Wang; Lei Cheng; Mei-Ping Lu
Journal:  Int J Clin Exp Med       Date:  2014-04-15

6.  Unveiling the principle of microRNA-mediated redundancy in cellular pathway regulation.

Authors:  Simon Fischer; René Handrick; Armaz Aschrafi; Kerstin Otte
Journal:  RNA Biol       Date:  2015       Impact factor: 4.652

7.  miR-20a regulates adipocyte differentiation by targeting lysine-specific demethylase 6b and transforming growth factor-β signaling.

Authors:  J Zhou; F Guo; G Wang; J Wang; F Zheng; X Guan; A Chang; X Zhang; C Dai; S Li; X Li; B Wang
Journal:  Int J Obes (Lond)       Date:  2015-03-30       Impact factor: 5.095

8.  Overexpressed let-7a inhibits glioma cell malignancy by directly targeting K-ras, independently of PTEN.

Authors:  Xi-Rui Wang; Hui Luo; Hai-Lin Li; Lei Cao; Xie-Feng Wang; Wei Yan; Ying-Yi Wang; Jun-Xia Zhang; Tao Jiang; Chun-Sheng Kang; Ning Liu; Yong-Ping You
Journal:  Neuro Oncol       Date:  2013-10-03       Impact factor: 12.300

9.  hsa-miR-520h downregulates ABCG2 in pancreatic cancer cells to inhibit migration, invasion, and side populations.

Authors:  F Wang; X Xue; J Wei; Y An; J Yao; H Cai; J Wu; C Dai; Z Qian; Z Xu; Y Miao
Journal:  Br J Cancer       Date:  2010-07-13       Impact factor: 7.640

Review 10.  MicroRNAs in colorectal cancer: translation of molecular biology into clinical application.

Authors:  Ondrej Slaby; Marek Svoboda; Jaroslav Michalek; Rostislav Vyzula
Journal:  Mol Cancer       Date:  2009-11-14       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.